|
1
|
Curado MP: Breast cancer in the world:
incidence and mortality. Salud Publica Mex. 53:372–384.
2011.PubMed/NCBI
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kelley SK and Ashkenazi A: Targeting death
receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol.
4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen
H, Shahrokh Z and Schwall RH: Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryo K, Kamogawa Y, Ikeda I, Yamauchi K,
Yonehara S, Nagata S and Hayashi N: Significance of Fas
antigen-mediated apoptosis in human fulminant hepatic failure. Am J
Gastroenterol. 95:2047–2055. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L,
Song N, Teng Y and Liu Y: Down-regulation of Cbl-b by bufalin
results in up-regulation of DR4/DR5 and
sensitization of TRAIL-induced apoptosis in breast cancer cells. J
Cancer Res Clin Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt
BR, Ho R, Ikegaki N and Brodeur GM: Resistance to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
in neuroblastoma cells correlates with a loss of caspase-8
expression. Cancer Res. 61:1314–1319. 2001.
|
|
8
|
Hyer ML, Croxton R, Krajewska M, Krajewski
S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM and Reed
JC: Synthetic triterpenoids cooperate with tumor necrosis
factor-related apoptosis-inducing ligand to induce apoptosis of
breast cancer cells. Cancer Res. 65:4799–4808. 2005. View Article : Google Scholar
|
|
9
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL- inducing apoptosis in cancer. Cancer Gene
Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh TR, Shankar S, Chen X, Asim M and
Srivastava RK: Synergistic interactions of chemotherapeutic drugs
and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2
ligand on apoptosis and on regression of breast carcinoma in vivo.
Cancer Res. 63:5390–5400. 2003.
|
|
11
|
Hesry V, Piquet-Pellorce C, Travert M,
Donaghy L, Jégou B, Patard JJ and Guillaudeux T: Sensitvity of
prostate cells to TRAIL-induced apoptosis increases with tumor
progression: DR5 and caspase 8 are key players. Prostate.
66:987–995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagane M, Pan G, Weddle JJ, Dixit VM,
Cavenee WK and Huang HJ: Increased death receptor 5 expression by
chemotherapeutic agents in human gliomas causes synergistic
cytotoxicity with tumor necrosis factor-related apoptosis inducing
ligand in vitro and in vivo. Cancer Res. 60:847–853. 2000.
|
|
14
|
Boulikas T and Vougiouka M: Recent
clinical trials using cisplatin, carboplatin and their combination
chemotherapy drugs. Oncol Rep. 11:559–595. 2004.PubMed/NCBI
|
|
15
|
Burtness B, Goldwasser MA, Flood W, Mattar
B and Forastiere AA; Eastern Cooperative Oncology Group. Phase III
randomized trial of cisplatin plus placebo compared with cisplatin
plus cetuximab in metastatic/recurrent head and neck cancer: an
Eastern Cooperative Oncology Group study. J Clin Oncol.
23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wiezorek J, Holland P and Graves J: Death
receptor agonists as a targeted therapy for cancer. J Clin Cancer
Res. 16:1701–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mandel RJ, Manfredsson FP, Foust KD,
Rising A, Reimsnider S, Nash K and Burger C: Recombinant
adeno-associated viral vectors as therapeutic agents to treat
neurological disorders. Mol Ther. 13:463–483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wagner JA, Reynolds T, Moran ML, Moss RB,
Wine JJ, Flotte TR and Gardner P: Efficient and persistent gene
transfer of AAV-CFTR in maxillary sinus. Lancet. 351:1702–1703.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Huang F, Cai H, Wu Y, He G and Tan
W: The efficacy of combination therapy using adeno-associated
virus-TRAIL targeting to telomerase activity and cisplatin in a
mice model of hepatocellular carcinoma. J Clin Cancer Res.
136:1827–1837. 2010. View Article : Google Scholar
|
|
20
|
Kanazawa T, Urabe M, Mizukami H, Okada T,
Kume A, Nishino H, Monahan J, Kitamura K, Ichimura K and Ozawa K:
γ-rays enhance rAAV-mediated transgene expression and cytocidal
effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene
Ther. 8:99–106. 2001.
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
|
|
22
|
Lin J, Zhang Z, Zeng S, Zhou S, Liu BF,
Liu Q, Yang J and Luo Q: TRAIL-induced apoptosis proceeding from
caspase-3-dependent and independent pathways in distinct HeLa
cells. Biochem Biophys Res Commun. 346:1136–1141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shankar S and Srivastava RK: Enhancement
of therapeutic potential of TRAIL by cancer chemotherapy and
irradiation: mechanisms and clinical implications. Drug Resist
Updat. 7:139–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shin EC, Seong YR, Kim CH, Kim H, Ahn YS,
Kim K, Kim SJ, Hong SS and Park JH: Human hepatocellular carcinoma
cells resist to TRAIL-induced apoptosis, and the resistance is
abolished by cisplatin. Exp Mol Med. 34:114–122. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu
Y and Zheng D: Synergistic antitumor effect of AAV-mediated TRAIL
expression combined with cisplatin on head and neck squamous cell
carcinoma. BMC Cancer. 11:54–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liping X, Shuping Y and Kaladhar BR:
Enhanced anticancer effect of the combination of cisplatin and
TRAIL in triple-negative breast tumor cells. Mol Cancer Ther.
10:550–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seol DW, Li J, Seol MH, Park SY, Talanian
RV and Billiar TR: Signaling events triggered by tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is
required for TRAIL-induced apoptosis. Cancer Res. 61:1138–1143.
2001.PubMed/NCBI
|
|
28
|
Brunetti G, Colucci S, Rizzi R, Mori G,
Colaianni G, Oranger A, Zallone A, Liso V and Grano M: The role of
OPG/TRA IL complex in multiple meloma: the OPG/TRAIL complex in an
in vitro osteoclastogenesis model derived from human multiple
meloma-bone disease. Ann NY Acad Sci. 1068:334–340. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sheridan JP, Marsters SA, Pitti RM, Gurney
A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood
WI, Goddard AD, Godowski P and Ashkenazi A: Control of
TRAIL-induced apoptosis by a family of signaling and decoy
receptors. Science. 277:818–821. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fulda S, Meyer E and Debatin KM:
Inhibition of TRAIL-induced apoptosis by BCL2 overexpression.
Oncogene. 21:2283–2294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Geelen CM, de Vries EG and de Jong S:
Lessons from TRAIL-resistance mechanisms in colorectal cancer
cells: paving the road to patient-tailored therapy. Drug Resist
Updat. 7:345–358. 2004.PubMed/NCBI
|
|
32
|
Vander Heiden MG, Chandel NS, Williamson
EK, Schumacker PT and Thompson CB: Bcl-Xl regulates the membrane
potential and volume homeostasis of mitochondria. Cell. 91:627–637.
1997.PubMed/NCBI
|
|
33
|
Harris MH and Thompson CB: The role of the
BCL2 family in the regulation of outer mitochondrial membrane
permeability. Cell Death Differ. 7:1182–1191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim IK and Jung YK, Noh DY, Song YS, Choi
CH, Oh BH, Masuda ES and Jung YK: Functional screening of genes
suppressing TRAIL-induced apoptosis: distinct inhibitory activities
of Bcl-XL and Bcl-2. Br J Cancer. 88:910–917. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee TJ, Lee JT, Park JW and Kwon TK:
Acquired TRAIL resistance in human breast cancer cells are caused
by the sustained cFLIP(L) and XIAP protein levels and ERK
activation. Biochem Biophys Res Commun. 351:1024–1030. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bellail AC, Tse MC, Song JH, Phuphanich S,
Olson JJ, Sun SY and Hao C: DR5-mediated DISC controls caspase-8
cleavage and initiation of apoptosis in human glioblastomas. J Cell
Mol Med. 14:1303–1317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang P, Zhang J, Anita B, Jiang W, Judith
H, Norman MK and Hao C: Inhibition of RIP and c-FLIP enhances
TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal.
19:2237–2246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brooks AD and Sayers TJ: Reduction of the
antiapoptotic protein cFLIP enhances the susceptibility of human
renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother.
54:499–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
